NCT02349542View on ClinicalTrials.gov

Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

November 1, 2016

Study Completion Date

November 21, 2016

Conditions
Arthroplasty, Replacement, KneePain
Interventions
DRUG

Liposomal bupivacaine

One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (\~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.

Trial Locations (1)

28209

OrthoCarolina, PA, Charlotte

All Listed Sponsors
lead

OrthoCarolina Research Institute, Inc.

OTHER

NCT02349542 - Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter